Medy Tox Inc
KOSDAQ:086900
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medy Tox Inc
Change in Working Capital
Medy Tox Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Medy Tox Inc
KOSDAQ:086900
|
Change in Working Capital
₩17.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Change in Working Capital
-₩938.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-13%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Change in Working Capital
₩7.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Change in Working Capital
₩3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Change in Working Capital
-₩6.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Change in Working Capital
-₩9.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Medy Tox Inc
Glance View
Medy-Tox, Inc. engages in the manufacture and sale of biopharmaceutical products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2009-01-16. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The firm provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The firm also engages in technology transfer. The firm distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
See Also
What is Medy Tox Inc's Change in Working Capital?
Change in Working Capital
17.3B
KRW
Based on the financial report for Dec 31, 2025, Medy Tox Inc's Change in Working Capital amounts to 17.3B KRW.
What is Medy Tox Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
11%
